April 2019, Vol 9, No 4

Pharmacy standards will be applied to medical practices, regardless of whether they have a pharmacy licensed with their state Board of Pharmacy. Read Article ›

In a first-in-human study of a novel bispecific T-cell engager (BiTE), AMG 420, when administered at a daily dose of 400 mcg, this novel drug-induced responses in 7 of 10 patients with heavily pretreated multiple myeloma in a phase 1 clinical trial, according to results presented at ASH 2018. Read Article ›

Page 2 of 2